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Abstract
Introduction:  Even  today,  the  treatment  of  intractable  vertigo  remains  a  challenge.  Vestibular
ablation with  intratympanic  gentamicin  stands  as  a  good  alternative  in  the  management  of
refractory vertigo  patients.
Objective:  To  control  intractable  vertigo  through  complete  saccular  and  horizontal  canal  ves-
tibular ablation  with  intratympanic  gentamicin  treatment.
Methods:  Patients  with  refractory  episodic  vertigo  were  included.  The  inclusion  criteria  were:
unilateral  ear  disease,  moderate  to  profound  sensorineural  hearing  loss,  and  failure  to  other
treatments.  Included  patients  underwent  0.5--0.8  mL  of  gentamicin  intratympanic  application
at a  30  mg/mL  concentration.  Vestibular  ablation  was  conﬁrmed  by  the  absence  of  response
on cervical  vestibular  evoked  myogenic  potentials  and  no  response  on  caloric  tests.  Audiome-
try, electronystagmography  with  iced  water,  and  vestibular  evoked  myogenic  potentials  were
performed  in  all  patients.
Results:  Ten  patients  were  included;  nine  patients  with  Meniere’s  disease  and  one  patient  with
(late onset)  delayed  hydrops.  Nine  patients  showed  an  absent  response  on  vestibular  evoked
myogenic  potentials  and  no  response  on  caloric  tests.  The  only  patient  with  low  amplitude
on cervical  vestibular  evoked  myogenic  potentials  had  vertigo  recurrence.  Vertigo  control  was
achieved in  90%  of  the  patients.  One  patient  developed  hearing  loss  >30  dB.
 Please cite this article as: Celis-Aguilar E, González RH, Hidalgo OV, Toledo HC. Refractory episodic vertigo: role of intratympanic
entamicin and vestibular evoked myogenic potentials. Braz J Otorhinolaryngol. 2016;82:668--73.
 This study was presented at the American Academy of Otolaryngology, 2014, Orlando, Florida.
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Conclusions:  Cervical  vestibular  evoked  myogenic  potentials  conﬁrmed  vestibular  ablation  in
patients treated  with  intratympanic  gentamicin.  High-grade  vertigo  control  was  due  to  complete
saccular  and  horizontal  canal  ablation  (no  response  to  iced  water  in  electronystagmography  and
no response  on  cervical  vestibular  evoked  myogenic  potentials).
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Vertigem  refratária  episódica:  papel  da  gentamicina  intratimpânica  e  potencial
evocado  miogênico  vestibular
Resumo
Introduc¸ão:  Ainda  hoje,  o  controle  da  vertigem  intratável  permanece  um  desaﬁo.  A  ablac¸ão
vestibular com  gentamicina  intratimpânica  permanece  como  uma  boa  alternativa  no  tratamento
de pacientes  com  vertigem  refratária.
Objetivo:  Controlar  a  vertigem  intratável  por  meio  de  ablac¸ão  vestibular  completa  dos  canais
sacular e  horizontal  com  gentamicina  intratimpânica  como  tratamento.
Método:  Pacientes  com  vertigem  refratária  episódica  foram  incluídos.  Os  critérios  de  inclusão
foram doenc¸a  unilateral  da  orelha,  perda  auditiva  neurossensorial  de  moderada  a  profunda
e fracasso  com  outros  tratamentos.  Os  pacientes  incluídos  receberam  uma  aplicac¸ão  de
0,5--0,8 mL  de  gentamicina  intratimpânica  com  concentrac¸ão  de  30  mg/mL.  A  ablac¸ão  ves-
tibular foi  conﬁrmada  pela  ausência  de  resposta  no  teste  de  potencial  evocado  miogênico
vestibular  cervical  (PEMVc)  e  nenhuma  resposta  nas  provas  calóricas.  Audiometria,  eletron-
istagmograﬁa  com  água  gelada  e  potencial  evocado  miogênico  vestibular  foram  realizados  em
todos os  pacientes.
Resultados:  Ao  todo,  dez  pacientes  foram  incluídos:  nove  com  doenc¸a  de  Ménière  e  um  com
hidropisia tardia.  Nove  pacientes  apresentaram  ausência  de  resposta  no  teste  de  potencial
evocado miogênico  vestibular  e  nenhuma  resposta  na  prova  calórica.  O  único  paciente  com
baixa amplitude  no  PEMVc  apresentou  recorrência  da  vertigem.  O  controle  da  vertigem  foi
obtido em  90%  dos  pacientes.  Um  paciente  desenvolveu  perda  auditiva  >  30  dB.
Conclusões:  O  PEMVc  conﬁrmou  ablac¸ão  vestibular  nos  pacientes  tratados  com  gentamicina
intratimpânica.  O  alto  grau  de  controle  da  vertigem  foi  devido  à  ablac¸ão  completa  do  sáculo
e canal  horizontal  (sem  resposta  à  água  gelada  na  eletronistagmograﬁa  e  ausência  de  resposta
no PEMVc).
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
c
a
c
b
b
ﬁ
(
d
(
r
t
c
t
cIntroduction
Vertigo  control  is  the  main  outcome  in  the  treatment
of  Meniere’s  disease;  nevertheless,  many  patients  do  not
respond  to  conservative  measures.  More  invasive  procedures
are  preserved  for  those  patients  with  intractable  vertigo
and  no  response  to  medical  treatment.  Surgical  treatments,
particularly  vestibular  nerve  section,  have  a  high  success
rate.  Nonetheless,  as  a  surgical  procedure,  side  effects  such
as  headache,  bleeding,  cerebrospinal  ﬂuid  (CSF)  leak,  or
facial  paralysis,  among  others,  are  possible.  For  this  reason,
intratympanic  gentamycin  treatment  is  gradually  replacing
these  surgical  procedures.
In  1957  Schuknecht1,2 was  the  ﬁrst  to  describe  the  use
of  aminoglucosides  in  the  treatment  of  Meniere’s  disease.
He  described  the  instillation  of  streptomycin  in  the  mid-
dle  ear  of  ﬁve  patients,  with  good  vertigo  control,  although
with  adverse  cochlear  side  effects,  as  profound  hearing  loss
developed  in  all  patients.
a
c
aSince  then,  numerous  studies  of  intratympanic  gentami-
in  have  demonstrated  a  76--96%  vertigo  control  rate,  with
 risk  of  hearing  loss  around  20--30%.1,2
Interestingly,  gentamicin  instillations  are  currently  still
ontroversial.  Dose,  number  of  applications,  and  period
etween  each  application  has  not  reach  a  consensus
etween  otologists.  In  2004,  a meta-analysis2 described
ve  different  techniques  of  gentamicin  applications:  daily
three  daily  applications  for  at  least  four  days),  weekly
ose  (one  each  week  for  a  total  of  four  doses),  low  dose
one  or  two  applications,  with  new  treatment  if  vertigo
ecurrence),  continuous  application  with  microcatheter,  and
itration  therapy  (weekly  or  daily  dose  until  vestibular  or
ochlear  symptoms  occur).  Chia  et  al.2 concluded,  according
o  this  meta-analysis,  that  the  best  method  of  gentami-
in  application  was  titration,  with  vertigo  control  as  high
s  81.7%.  These  authors  did  not  ﬁnd  statistical  signiﬁ-
ance  difference  between  partial  vs.  complete  vestibular
blation.
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Statistical  analysis70  
On  the  other  hand,  cervical  vestibular  evoked  myogenic
otentials  (cVEMPs)  were  ﬁrst  described  by  Colebatch  in
9943;  since  then,  cVEMPs  have  been  a  known  test  for  saccu-
ar  function  and  inferior  vestibular  nerve.  In  humans,  intense
uditory  clicks  and  tone  bursts  stimulate  afferent  saccu-
ar  pathways  that  inhibit  sternocleidomastoid  muscle  tone,
hich  is  recorded  on  this  test.  The  result  is  a  positive  wave
1,  followed  by  a  negative  wave  n1.
Furthermore,  saccular  function  has  been  found  altered
n  patient  with  recently  diagnosis  of  Meniere’s  disease.4 It  is
elieved  that  complete  vestibular  function,  including  saccu-
ar  function,  should  be  measured  in  gentamicin  treatment.
oreover,  the  rehabilitation  of  a  patient  who  undergoes
entamicin  treatment  depends  on  the  amount  of  vestibular
amage  present.5
Disadvantages  of  intratympanic  gentamicin  are  mainly
earing  loss6 and  chronic  subjective  dizziness.
Evaluation  of  the  saccular  function  is  paramount  if  the
oal  of  vestibular  ablation  with  intratympanic  gentamicin  is
omplete  ablation,  and  cVEMPs  could  add  to  the  diagnostic
ork-up  and  follow-up  of  these  patients.  This  test  could  also
how  vestibular  residual  function  in  a  patient  with  recurrent
ertigo  post-gentamicin  treatment.
Complete  vestibular  ablation  vs.  partial  ablation  is  a
ubject  of  controversy.  Unfortunately,  reports  on  how  this
estibular  ablation  is  obtained  are  varied.  To  determine
omplete  vestibular  ablation,  studies  should  include  evalua-
ion  of  semicircular  canals,  as  well  as  utricular  and  saccular
unction.
Vestibular  ablation  in  this  study  was  deﬁned  as  zero
esponse  on  the  caloric  tests  with  ice  water  and  absent
esponse  on  cVEMPs,  i.e., complete  ablation  of  saccular  and
orizontal  semicircular  canal  function.
The  objective  of  this  study  was  to  assess  vertigo  con-
rol  in  patients  with  intractable  refractory  vertigo  treated
ith  intratympanic  gentamicin  and  vestibular  ablation,  con-
rmed  by  an  absent  response  on  cVEMPs  and  zero  response
n  the  ice  water  test  on  electronystagmography  (ENG).
ethods
tudy  design
etrospective,  clinical  chart  review.
etting
ertiary  care  center.
atients
his  study  included  patients  with  intractable  recurrent  ver-
igo,  unilateral  vestibular  disease,  and  complete  vestibular
ests,  from  January  2002  to  December  2010.  Weekly  gen-
amicin  application  was  conducted  in  all  patients.  The
pplication  consisted  of  0.5  ml  to  0.8  ml  of  gentamicin,  with concentration  of  30  mg/mL.  This  solution  was  buffered
ith  bicarbonate.  Inclusion  criteria:  All  patients  fulﬁlled  the
riteria  for  Meniere’s  disease  according  to  the  1995  AAO-HNS
ommittee  on  hearing  and  equilibrium,  had  age  >18  years,
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oderate  to  profound  hearing  loss,  and  failure  to  other
edical  treatments  including  dexamethasone  intratympanic
pplication.
easurements
ll  patients  underwent  pure  tone  audiometry  and  speech
udiometry  with  an  Interacoustic  AD29  audiometer.  ENG  was
erformed  with  micromedical  equipment.  Oculomotor  tests
saccades,  gaze  testing,  optokinetic,  smooth  pursuit  track-
ng),  positional  tests,  and  caloric  tests  were  performed  in
ll  patients.  Vestibular  asymmetry  was  deﬁned  through  the
aloric  tests,  with  an  asymmetry  of  30%  compared  to  the
ther  ear.  Zero  response  was  deﬁned  as  absence  of  nystag-
us  with  iced  water.
cVEMPs  were  performed  with  Nicolet  Viking  Select
onsisted  of  electrodes  placed  on  the  sternocleidomastoid,
ternum,  and  ipsilateral  mastoid  (ground  electrode).  Stern-
cleidomastoid  tone  was  obtained  by  effort  elicited  by  the
atient  by  means  of  a  pole  system  with  a  weight  of  2  kg
nd  a  headband.  The  patient  thrusts  forward  his/her  fore-
ead,  maintaining  muscle  tone.  Auditory  stimuli  consisted  of
licks,  three  per  second  at  105  dB  (with  a  contralateral  white
oise  of  45  dB,  and  a ﬁlter  of  10  Hz--1.5  kHz).  Recordings
ere  conducted  for  100  ms  (milliseconds).
Informed  consent  was  obtained  from  all  patients.  This
tudy  was  approved  by  the  institutional  ethics  committee.
ntervention
rotocol  of  intratympanic  gentamicin  application:  patient
ays  ﬂat  with  45◦ of  head  rotation,  tetracaine  solution  is
pplied  to  ear  canal,  under  microscopic  view  the  anesthetic
s  suctioned,  and  with  a 1  mL  syringe  with  30  mg  gentamicin,
uffered  with  1/3  NaHCO3;  0.4  ml  to  0.6  ml  is  applied  to
he  middle  ear,  in  the  inferior  quadrants.  The  patients  rests
n  that  position  for  over  one  hour,  and  is  instructed  to  not
peak  or  swallow.  Weekly  applications  were  performed  until
here  was  an  absent  response  both  to  ice  water  ENG  and
VEMPs.
ollow-up
atients  were  followed  up  with  evaluations  at  30  days,  and
hree,  six,  and  12  months.  Posterior  to  these  evaluations,
ollow  up  was  done  annually.  All  patients  underwent  a  vesti-
ular  rehabilitation  program,  which  consisted  of  enhancing
he  vestibulo-ocular  reﬂex,  sensory  substitution,  and  pos-
ural  control;  each  protocol  was  individualized.  During  the
atients’  subsequent  visits,  audiometry  was  performed,  as
ell  as  ENG  with  ice  water  and  measurement  of  the  func-
ional  scale  of  Meniere’s  disease.tatistical  analysis  was  performed  using  SPSS  15.0.  The  sta-
istical  analysis  included  descriptive  statistics  (mean  and
tandard  deviation).
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Table  1  Patients’  clinical  characteristics,  intervention,  and  follow  up.
No.  Age  Sex  Caloric  test  (◦)  Caloric  test  (◦)  cVEMPs  Post  No.  IT  Vertigo  Follow  up  (years)  PTA  dB  difference
Before After
1  69  F  20  0  Low  amplitude  5/11  +  3  −2.5
2 55  M  0  NR  7  --  1  11.25
3 25  M  0  0  NR  1  --  4  12.5
4 42  F  6  0  NR  6  --  3  −1.67
5 60  F  53  0  NR  5  --  4  26.25
6 46  F  12  0  NR  3  --  5  −8.75
7 38  F  5  iced  water  0  NR  2  --  7  −2.5
8 45  M  0  NR  4  --  1.5  −41.6
9 64  F  6  0  NR  5  --  7  9
10 33  M  8  0  NR  5  --  7  0
PTA difference, pure tone average difference (difference of dB in audiometry pre- and post-intervention); negative values represent
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No. IT, number of intratympanic gentamicin applications; NR, no r
Results
Ten  patients  were  included  with  complete  vestibular  tests,
both  ENG  and  cVEMPs.  Nine  patients  had  Meniere’s  disease
and  one  patient  had  delayed  endolymphatic  hydrops.
All  patients  underwent  intratympanic  gentamicin  appli-
cation.  The  mean  number  of  applications  was  4.3  (range
1--7).  Follow-up  was  from  one  to  seven  years,  with  a  mean
of  4.25  years.
Vertigo  control  was  90%.  One  patient  developed  hearing
loss  >30  dB.  See  Table  1  for  results.
After  gentamicin  treatment,  nine  patients  had  absent
response  on  cVEMPs  and  only  one  patient  had  persistent
cVEMPs  response.  The  latter  patient  (patient  No.  1  on  the
table)  had  low  amplitude  cVEMPs  with  symptomatic  recur-
rent  vertigo.  This  patient  required  two  sets  of  gentamicin
applications;  ﬁve  and  11  applications,  respectively.
All  patients  had  zero  response  on  ice  water  ENG  posterior
to  gentamicin  application.  ENG  oculomotor  and  positional
tests  were  negative  in  all  patients.
Two  patients  (patients  No.  2  and  8)  had  ENG  with  vesti-
bular  asymmetry  pre-treatment  (>25%),  although  no  grades
of  response  were  documented;  therefore,  this  data  is  not
included  on  Table  1.
Previous  treatment
All  patients  had  no  response  to  medical  treatment  (diet,
diuretics,  steroids,  vasodilators,  calcium  antagonists).  Inter-
estingly,  two  patients  had  dexamethasone  intratympanic
application  without  good  results,  as  well  as  one  patient  with
endolymphatic  sac  decompression  and  one  patient  with  pos-
sible  incomplete  vestibular  nerve  section.
cVEMPS  previous  to  gentamicin  application
Even  though  all  patients  had  documented  vestibular  paresis
(horizontal  semicircular  canal  paresis)  previous  to  gentami-
cin  treatment,  only  two  (patients  No.  3  and  4)  had  initial
pre-treatment  cVEMPs.  Both  patients  had  low  amplitude
response  cVEMPs  with  posterior  ablation  of  this  response.
r
s
w
ense; cVEMPs, cervical vestibular evoked myogenic potentials.
hese  patients  had  Meniere’s  disease,  with  a mean  age  of
3.5  years.
VEMPs  and  vertigo  control
inety  percent  of  the  patients  had  good  vertigo  control.  The
nly  patient  with  recurrent  vertigo  attacks  was  positive  on
VEMPs  posterior  to  the  second  course  of  gentamicin  appli-
ation.  This  patient  rejected  surgical  treatment  and  was
ubsequently  partially  controlled  with  medical  treatment.
earing  loss
nly  one  patient  had  hearing  loss  more  than  30  dB.  The  rest
f  patients  had  a  mean  hearing  loss  of  5.70  dB.
unctional  class  of  Meniere’s  disease
ive  patients  had  intermittent  dizziness;  they  continue  to
ork,  drive,  and  engage  in  any  activity.  This  corresponds  to
unctional  class  levels  2  and  3.
echnical  difﬁculties  of  cVEMPs
our  patients  had  to  be  eliminated  from  the  database
ecause  of  bilateral  absent  response  on  cVEMPs.  These  tech-
ical  difﬁculties  were  due  to  morphological  neck  variations
thick  neck)  or  due  to  lack  of  cooperation  from  the  patient
no  sternocleidomastoid  contraction).
iscussion
he  purpose  of  this  study  was  to  corroborate  complete  ves-
ibular  ablation  by  means  of  a  zero  response  of  ice  water
n  ENG  and  an  absent  cVEMPs  response.  cVEMPs  conﬁrmed
n  absent  saccular  function  and  a  non-functional  poste-
ior  semicircular  canal.  On  the  other  hand,  the  horizontal
emicircular  canal  was  measured  by  zero  response  on  ice
ater  with  ENG.  Thus,  almost  all  of  the  functional  vestibular
pithelium  was  measured  and  complete  vestibular  ablation
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saccular  and  horizontal  semicircular  canal  function)  could
e  achieved.
In  this  series,  absent  response  on  cVEMPs  test  after  genta-
icin  treatment  was  present  in  all  patients  with  good  vertigo
ontrol.
Additionally,  an  abnormal  response  to  cVEMPs  could  be
n  early  symptom  of  Meniere’s  disease.  In  pre-symptomatic
ars,  it  could  be  a  sign  of  disease  in  the  contralateral  ear.4,7
In  the  present  study,  two  patients  (patients  No.  3  and
)  had  positive  cVEMPs  pre-treatment,  and  interestingly,
oth  had  low  amplitude  response.  This  corroborates  what
as  previously  been  described  in  the  literature,  that  saccu-
ar  damage  is  present  in  Meniere’s  disease.4,5 Other  authors
ave  described  an  initial  damage  to  semicircular  canals  with
osterior  saccular  injury.5
Patient  No.  3  was  a  controversial  case,  since  there
as  zero  response  on  ice  water  ENG  but  cVEMPs  response
as  present;  gentamicin  treatment  was  chosen  due  to
ersistent  saccular  function.  After  gentamicin  application,
VEMPs  were  negative  and  ice  water  ENG  persisted  nega-
ive  after  two  years  posterior  to  intervention.  During  this
ime  posturography  was  normal,  verifying  complete  vesti-
ular  rehabilitation.  This  patient  is  free  of  vertigo  attacks.
cVEMPs  could  be  of  great  diagnostic  value  when  a  patient
resents  with  vertigo  spells  and  no  response  on  ice  water
NG,  since  another  vestibular  epithelium,  e.g.  the  saccule,
ould  be  responsible  for  the  vertigo  attacks.
Animal  studies  have  proved  that  cervical  VEMPs  originate
rom  type  I  cells  in  the  saccule  of  guinea  pigs.8 Vestibular  cell
egeneration  after  gentamicin  has  been  described  in  both
emicircular  canals8 and  the  saccule.7 This  vestibular  regen-
ration  is  probably  the  cause  of  recurrent  vertigo  attacks
ost-gentamicin.9 However,  other  authors  explain  that  this
s  due  to  the  natural  history  of  Meniere’s  disease,  since  the
bsence  of  vertigo  attacks  in  some  studies  is  due  to  an  insuf-
cient  follow-up,  giving  a  false  idea  of  therapy  success.  Long
erm  follow-up  is  strongly  advised.7
In  the  present  series,  patient  No.  1,  after  the  ﬁrst  therapy
f  gentamicin,  had  grade  11  vestibular  response  on  ice  water
NG  and  also  presented  with  low  amplitude  cVEMPs.  After
he  second  application  of  gentamicin,  she  persisted  with
ertigo  attacks  with  positive  cVEMPs,  supporting  the  asso-
iation  of  vestibular  tests  and  symptoms,  already  described
y  numerous  authors.5,7,9,10
Helling  et  al.5 included  in  their  study  19  patients  with
eniere’s  disease.  After  the  ﬁrst  gentamicin  application
VEMPs  were  negative,  they  concluded  that  cVEMPs  were  not
 reliable  indicator  of  therapy  success.  This  differs  from  the
resent  results  since  the  only  patient  with  positive  cVEMPS
as  the  patient  who  had  recurrent  vertigo.  Additionally,  Pic-
iotti  et  al.11 emphasized  the  used  of  cVEMPs  to  monitor
herapy  efﬁcacy.
Presence  of  cVEMPs  after  intratympanic  gentamicin  could
e  an  indicator  of  therapy  failure,  at  least  in  the  present
tudy.  More  research  is  mandatory  in  order  to  conﬁrm  these
esults.
Additionally,  intratympanic  gentamicin  delivery  methods
re  highly  variable.  According  to  Chia  et  al.,2 the  titration
ethod  demonstrated  vertigo  control  of  81.7%  vs.  75%  for
eekly  delivery.  The  authors’  standard  delivery  method,  as
reviously  stated,  is  weekly  applications  until  no  response
n  ice  water  ENG.  Comparing  these  results  with  those
t
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reviously  published,  this  study’s  rate  of  vertigo  control
ould  be  superior  to  other  methods  of  gentamicin  delivery.
Complete  vestibular  ablation  is  still  controversial,  more
o  since  the  meta-analysis  by  Chia  et  al.2 did  not  conﬁrm
 statistical  difference  between  partial  and  complete  ves-
ibular  ablation  (p  =  0.179).  The  data  show  that  complete
estibular  ablation  in  this  meta-analysis  produced  92.1%  ver-
igo  control  vs.  74.8%  for  partial  ablation.
Other  authors5 have  preferred  partial  ablation,  explain-
ng  that  preserved  canalicular  function  could  achieve  vertigo
ontrol,  because  it  produced  a more  speciﬁc  damage  to  the
ark  cells  and  thus  provides  endolymph  production  homeo-
tasis.  Nevertheless,  the  present  study  demonstrates  that
estibular  ablation  (as  measured  by  saccular  and  horizontal
emicircular  canal  ablation)  is  effective  for  vertigo  control.
Chia  et  al.2 described  a  13.1%  hearing  loss  with  the
eekly  gentamicin  delivery  method.  In  the  present  series,
nly  one  patient  had  hearing  loss  greater  than  30  dB,  10%
f  the  study  population.  None  of  the  patients  had  profound
earing  loss  secondary  to  the  procedure,  vs.  6.6%  reported
n  other  literature.2 The  mean  hearing  loss  was  5.7  dB.  This
ate  of  hearing  loss  is  corroborated  by  other  studies.5 Of
elevance,  there  are  other  centers  that  apply  intratympanic
entamicin  in  normal  hearing  subjects,12 emphasizing  the
ow  rate  of  expected  hearing  loss.
Interestingly,  in  this  series,  four  patients  had  pure  tone
verage  (PTA)  improvement.  This  could  be  due  to  the  nat-
ral  course  of  Meniere’s  disease,  which  includes  ﬂuctuating
earing  loss.
Utricular  function  has  been  described  to  be  preserved
n  30%--40%  of  patients  with  intratympanic  gentamicin
reatment5;  this  differs  from  the  saccule  and  semicircu-
ar  canals,  which  are  invariable  injured  by  this  treatment.
nfortunately,  this  study  did  not  evaluate  utricular  func-
ion.  Posturography  has  also  been  used  in  these  patients.
ne  study  described  an  improvement  in  the  vestibular  com-
onent  six  months  after  gentamicin  middle  ear  application.
here  are  several  venues  of  research  that  have  been  incom-
letely  explored  regarding  this  treatment  that  could  be  of
se  by  future  researchers.
The  limitations  of  this  study  are  its  retrospective  nature,
he  limited  number  of  patients  included,  and  the  lack  of  pre-
reatment  cVEMPs  in  some  patients.  However,  one  strength
f  this  study  is  the  long-term  follow-up,  in  some  patients  up
o  seven  years.
Another  limitation  is  the  fact  that  the  ENG  caloric  test
epresents  only  a  low  frequency  test  of  vestibular  function.
he  caloric  test  measures  exclusively  the  horizontal  semi-
ircular  canal  function;  therefore,  it  can  be  inferred  that
n  this  study,  only  partial  vestibular  ablation  was  measured.
evertheless,  the  ENG  also  measures  a dynamic  range  of
ther  tests,  such  as  positional  testing  and  oculomotor  tests
saccades,  optokinetic,  smooth  pursuit,  etc.), which  were
ot  altered  in  any  of  our  patients.
The  rotational  chair  test  also  evaluates  the  vestibulo-
cular  reﬂex  (VOR)  and  the  horizontal  semicircular  canal;
his  test  can  be  implemented  for  patients  in  whom  it  is  dif-
cult  to  perform  caloric  stimulation  and  adds  accuracy  to
he  ENG;  nonetheless,  this  test  was  not  performed  in  the
resent  patients.  Additionally,  both  the  caloric  test  and  the
otational  chair  test  quantify  the  VOR  reﬂex  on  the  horizon-
al  plane  and  at  low-frequency.  The  vestibule  ocular  reﬂex
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can  also  be  evaluated  by  the  head  impulse  test,  with  or  with-
out  Frenzel  goggles;  caloric  tests  could  also  be  performed
if  necessary,  with  only  Frenzel  goggles  at  the  emergency
department.
Moreover,  the  authors  are  aware  of  the  lack  of  other
vestibular  tests,  such  as  ocular  VEMPs,  video  head  impulse
test,  and  utricular  function.  In  this  study,  although  a  com-
plete  absence  of  the  saccule  and  horizontal  semicircular
canal  function  was  achieved,  complete  vestibular  function
cannot  be  assumed  because  not  all  vestibular  organs  were
measured.
Nevertheless,  this  study  adds  evidence  on  the  use  of
intratympanic  gentamicin  for  complete  ablation  of  saccule
and  horizontal  semicircular  canal  function.  ENG  caloric  tests
and  cVEMPs  should  be  use  to  corroborate  vestibular  ablation.
Conclusions
cVEMPs  conﬁrmed  vestibular  ablation  in  patients  treated
with  intratympanic  gentamicin.  High-grade  vertigo  control
was  due  to  complete  saccular  and  horizontal  semicircular
canal  ablation  (no  response  to  iced  water  in  ENG  and  no
response  on  cVEMPs).
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